

Assessment

Cite this article: Wallut L, Peyron C, Hervieu-Bègue M, Osseby G-V, Giroud M, Legris N, Quantin C, Béjot Y, Lejeune C (2020). Efficiency of telemedicine for acute stroke: a cost-effectiveness analysis from a French pilot study. *International Journal of Technology Assessment in Health Care* **36**, 126–132. <https://doi.org/10.1017/S0266462320000057>

Received: 3 July 2019

Revised: 12 December 2019

Accepted: 14 January 2020

First published online: 2 March 2020

Key words:

Cost-effectiveness; decision analysis model; telemedicine; stroke

Author for correspondence:

Laure Wallut,

E-mail: laure.wallut@u-bourgogne.fr

Efficiency of telemedicine for acute stroke: a cost-effectiveness analysis from a French pilot study

Laure Wallut¹ , Christine Peyron¹, Marie Hervieu-Bègue², Guy-Victor Osseby², Maurice Giroud², Nicolas Legris², Catherine Quantin^{3,4,5,6}, Yannick Béjot² and Catherine Lejeune⁵

¹Laboratoire d'Économie de Dijon, EA (7467), Université de Bourgogne-Franche-Comté, Pôle d'Économie et de Gestion, 2 bd Gabriel – BP 26 611, 21066 Dijon cedex, France; ²Dijon Stroke Registry, EA7460, Dijon University Hospital, University of Burgundy and Medical School of Dijon, Dijon, France; ³CHRU Dijon, Service de Biostatistiques et d'Information Médicale (DIM), Dijon, F-21000, France; ⁴Univ. Bourgogne Franche-Comté, Dijon, F-21000, France; ⁵Inserm CIC 1432, Clinical Epidemiology Unit, Dijon University Hospital, Dijon, France and ⁶Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), INSERM, UVSQ, Institut Pasteur, Université Paris-Saclay, Paris, France

Abstract

Objectives. Telestroke is an effective way to improve care and health outcomes for stroke patients. This study evaluates the cost-effectiveness of a French telestroke network.

Methods. A decision analysis model was built using population-based data. We compared short-term clinical outcomes and costs for the management of acute ischemic stroke patients before and after the implementation of a telestroke network from the point of view of the national health insurance system. Three effectiveness endpoints were used: hospital death, death at 3 months, and severe disability 3 months after stroke (assessed with the modified Rankin scale). Most clinical and economic parameters were estimated from the medical files of 742 retrospectively included patients. Sensitivity analyses were performed.

Results. The analyses revealed that the telestroke strategy was more effective and slightly more costly than the reference strategy (25 disability cases avoided *per* 1,000 at 3 months, 6.7 avoided hospital deaths, and 13 avoided deaths at 3 months for an extra cost of EUR 97, EUR 138, and EUR 154, respectively). The results remained robust in the sensitivity analyses.

Conclusions. In France, telestroke is an effective strategy for improving patient outcomes and, despite the extra cost, it has a legitimate place in the national health care system.

Background

Stroke is a major public health priority worldwide due to its frequency and severity, and it is a leading cause of disability and death in the adult population of developed countries (1). Acute ischemic stroke (AIS) accounts for about 80 percent of all strokes (2). Systemic intravenous (IV) thrombolysis and management in a stroke unit have been proven to improve the clinical outcomes of AIS patients (3–5). Access to stroke care is an emergency since IV thrombolysis needs to be administered within a restricted time window: 3 up to a maximum of 4.5 h in a stroke center (6). Despite clear evidence and guidelines, access to stroke care remains insufficient and IV thrombolysis underused with rates below 5 percent (7). The main barriers are the lack of facilities (neurologists) and geographic distance (8). In this context, telemedicine is an opportunity to improve access to a stroke unit and to reduce the time from symptom onset to needle time. Telemedicine applied to stroke is known as telestroke (9). Its goal is to enable the remote evaluation of patients by a neurologist and the delivery of IV thrombolysis (telethrombolysis). The use of telestroke has spread considerably over the last decade (10). In France, the region of Burgundy was chosen to pilot a telestroke network, called the TeleAVC Burgundy network, which was implemented in 2012 (11). The TeleAVC Burgundy network is a hub-and-spoke shaped network that connects 13 local hospitals (spokes) to two stroke units (hubs). In the local hospitals, patients are remotely managed by the stroke unit neurologist for evaluation, diagnosis, and the decision to initiate thrombolysis, and afterwards they are sent to the stroke unit for post-thrombolysis monitoring. This approach is an effective way to reduce the time from onset to treatment and to improve clinical outcomes (10;12;13).

Economic issues must also be addressed because stroke generates major in-hospital and rehabilitation costs (14). Several previous studies have assessed the cost-effectiveness of telestroke (15–20), and most demonstrated potential savings and improved health care outputs over a long-term horizon (15–19). Moreover, all of these published studies, except one (19), relied mainly on estimates from the literature. A recent study showed beneficial effects over




Fig. 1. Decision-analysis model.

3 months, but the network under study was dedicated to general neurological teleconsultations rather than stroke care (20). These factors limit the transferability of the published results to the French context. Therefore, the aim of the current study was to evaluate the short-term clinical outcomes and costs for AIS patients managed by a telestroke network compared with usual care. Our work was based on a decision analysis model using French population-based data.

Material and Methods

Study Population

We conducted a multicenter before–after study that included a total of 742 patients (21). Included patients met the following criteria: adults hospitalized for ischemic stroke, confirmed by imaging or a neurologist (CIM-10 diagnosis codes I63; I64 and G46), from 1 October 2010 to 30 September 2013. These patients were retrospectively identified from the administrative claims data of five of the 13 hospitals (in Auxerre, Mâcon, Nevers, Semur-en-Auxois, and Sens) that were connected with the two regional stroke units (in Dijon and Chalon-sur-Saône). We chose the five local hospitals that were already using telestroke on a routine basis in 2012.

Eligible patients were then assigned to two periods: the “before” phase (1 October 2010 to 30 September 2011) and the “after” phase (1 October 2012 to 30 September 2013). Patients who received endovascular treatment in addition to IV thrombolysis were excluded seeing as endovascular procedures were only performed at the Dijon University Hospital by trained neuroradiologists.

The baseline characteristics (age, gender, NIHSS score) of patients in the before and after phases were compared at a 5 percent

level. The demographic and clinical characteristics did not differ significantly (Supplementary Table 1 – unpublished data).

Permission to collect retrospective patient data was granted by decision DR-2014-115 of the French “*Commission Nationale de l’Informatique et des Libertés*.”

Model Overview

A decision analysis model was built using Tree Age Pro Healthcare 2014 v2.2 software (TreeAge Inc, Williamstown, MA). Two strategies were compared: the first was usual care (before 2012) and the second was telestroke care. All clinical events in the two competing strategies were associated with estimated conditional transition probabilities. At the end of each alternative arm of the decision tree, two payoffs were assigned, corresponding to the total cost of care and the effectiveness.

As shown in Figure 1, patients entered the model by presenting with AIS. Before the implementation of the telestroke network, two types of access to the hospital care were modeled at stroke onset: emergency medical regulation or self-referring. In the case of emergency medical regulation, the patient was referred to one of the two stroke units; in the other case, we assumed that the patient self-referred to the closest hospital (with or without a stroke unit). If there were no contraindications, stroke unit patients received IV thrombolysis. Patients admitted to the local hospital could be transferred to the stroke unit and receive IV thrombolysis under the same indications. The criteria for transfer were age, severity of stroke, and time from stroke onset. Alternative treatment and monitoring was provided to patients who did not receive thrombolysis. The complications associated with stroke were also taken into account. Because intracerebral

hemorrhage complications are potential complications of IV thrombolysis, they were aggregated with post-stroke complications in relevant cases. After 2 days of monitoring in the stroke unit, thrombolysis patients were eligible for transfer to rehabilitation care. The patients who received an alternative treatment were also eligible for transfer to rehabilitation care depending on their condition. The payoffs for each branch were the resulting health states and costs. We modeled three options for health states: hospital death, death at 3 months, and disability 3 months after stroke, according to the level of severity.

The sequencing of clinical events after the implementation of the telestroke network was quite similar to the usual care strategy, but there was one important difference: in case of emergency medical service activation, the stroke patient was systematically referred to the nearest hospital (with or without a stroke unit). Therefore, stroke patients could be examined remotely by a neurologist in conjunction with a local physician; IV thrombolysis was administered *in situ* if required, and the patient was necessarily transferred to the stroke unit for medical monitoring.

Model Parameters

Event Probabilities

Most of the model parameters were based on data from the medical files of the 742 included patients. The files were obtained from emergency regulation services and various hospital departments (i.e. emergency services, neurology and medical services, or rehabilitation services) of the five local hospitals and the two stroke units. The model parameters were: the probability that a patient called emergency medical service, the probability that a patient received IV thrombolysis or experienced post-stroke complications, and all data relative to the effectiveness criteria (hospital death, death at 3 months, and disability associated with stroke at 3 months) (Table 1).

The probability that a patient would have symptomatic hemorrhagic transformations (SHT) associated with IV thrombolysis was the only clinical data taken from the literature. The probability of SHT was based on a study of the TeleAVC Burgundy network (13). In this study, SHT were recorded according to the National Institute of Neurological Disorders and Stroke criteria (3).

Finally, we applied event probabilities (thrombolysis, post-stroke complications, death, and disability) from the usual care strategy to the “stroke unit self-referring patients” event, since no thrombolysis patients were obtained with the random selection. This imputation was possible because the management of stroke patients was similar before and after the implementation of telestroke and because stroke severity, assessed by NIHSS score, was also similar in both groups.

Effectiveness

The model was built over a time horizon of 3 months so that the stroke outcomes would be stabilized (22). Three effectiveness endpoints were used: (1) hospital death, (2) death at 3 months, and (3) associated disability 3 months after stroke. Hospital deaths included deaths that occurred during the hospital stay (in the stroke unit or local hospital); deaths that occurred in the rehabilitation unit were excluded. Death at 3 months included deaths that occurred after hospital discharge (death in the rehabilitation unit, at home, or other).

For the analysis, we allocated a score of 1 for death and 0 for survival. Disability after stroke at 3 months was evaluated with the dedicated modified Rankin scale (mRs) score. The scale ranges from 0 (no disability) to 5 (bedridden); 6 refers to death.

Moderate disability is an mRs score of 1 to 2, and severe disability from 3 to 5. For the analysis, we assigned a score of 1 for severe disability and 0 for moderate disability.

Costs

Only direct medical costs were included in the analysis (Table 1). They included the health expenditures related to the hospital and rehabilitation stays, all of which were fully covered by the national health insurance system.

Cost of hospital stay. All patients were hospitalized. We modeled the costs of hospital stays for three treatment options: thrombolysis patients (stroke unit), telethrombolysis patients (local hospital), and alternative treatment patients (patients who did not receive thrombolysis). The average cost and length of stay (LOS) for telethrombolysis patients and alternative treatment patients were taken from two French studies (23;24).

Cost of rehabilitation stay. The cost of the rehabilitation stay was estimated using the average daily cost for rehabilitation and the average LOS in a rehabilitation unit. The average daily cost for rehabilitation was taken from French literature (24). The average LOS in a rehabilitation unit was based on the 742 included patients. In case of missing data, we assumed that thrombolysis and telethrombolysis patients had the same average length of rehabilitation stay. We then adjusted the cost of the rehabilitation stay for the three treatment options. The adjustment was based on the average LOS by the level of disability (severe or moderate) in stroke survivors and on the average LOS in case of death.

Efficiency

Usual care was used as the reference strategy. The cost-effectiveness analysis was based on the calculation of an incremental cost-effectiveness ratio (ICER) for each of the three effectiveness criteria (hospital death, death at 3 months, and disability 3 months after stroke). The ICER referred either to the cost by additional fatality case prevented (hospital death or death at 3 months) or to the cost by additional severe disability prevented. In each case, the ICER was calculated by dividing the incremental expected cost by the incremental expected effectiveness of the two alternative strategies according to the following formula: $ICER = (\text{Mean Cost}_{\text{telestroke}} - \text{Mean Cost}_{\text{usual care}}) / (\text{Mean effectiveness}_{\text{telestroke}} - \text{Mean effectiveness}_{\text{usual care}})$. The period was less than one year, so the costs and effectiveness were not discounted.

Sensitivity Analyses

Sensitivity analyses were performed, which allowed us to test the robustness of the model (21). All of these analyses focused on the length of stay in the rehabilitation unit because it was the main component of the total cost. The goal was to determine whether varying the lengths of the rehabilitation stay according to treatment and post-stroke disability affected the results of the model. The first analysis, entitled “global rehabilitation LOS”, examined the length of rehabilitation stay whatever the treatment (telethrombolysis, thrombolysis or alternative treatment) and the post-stroke level of disability ($mRs \leq 2$ or >2). The other sensitivity analyses focused on the length of rehabilitation stay for several patient profiles: 1. “Rehabilitation LOS alternative treatment ($mRs > 2$)” focused on patients who received alternative treatment and with $mRs > 2$ (baseline value: 68 days; min: 2 days; max: 235 days); 2. “Rehabilitation LOS alternative treatment ($mRs \leq 2$)” focused on patients treated with alternative treatment and with $mRs \leq 2$ (baseline value: 46 days; min: 3 days; max: 175 days); 3. “Rehabilitation LOS thrombolysis and telethrombolysis ($mRs > 2$)” focused on patients

Table 1. Model parameters

Transitions probabilities ^a	Usual care (<i>n</i> = 371)	Telestroke (<i>n</i> = 371)	Sources
EMR	.64	.67	Medical file
EMR and referring to stroke unit	–	.58	Medical file
EMR and referring to local hospital	–	.42	Medical file
Self-referring	.36	.33	Medical file
Self-referring to stroke unit	.44	.46	Medical file
Self-referring to local hospital	.56	.54	Medical file
Transfer to stroke unit	.04	–	Medical file
IV thrombolysis	.12	.15	Medical file
Stroke unit		.20	Medical file
Local hospital		.09	Medical file
SHT	.06	.06	(10)
Post-stroke complications	.25	.32	Medical file
Stroke unit		.27	Medical file
Local hospital		.37	Medical file
Hospital death	.06	.06	(10)
Stroke unit		.05	Medical file
Local hospital		.10	Medical file
Death at 3 months	.14	.13	Medical file
Stroke unit		.10	Medical file
Local hospital		.17	Medical file
Survival with moderate disability	.83	.86	Medical file
Stroke unit		.83	Medical file
Local hospital		.86	Medical file
Survival with severe disability	.16	.14	Medical file
Stroke unit		.14	Medical file
Local hospital		.14	Medical file
Cost categories mean EUR (min-max)			
Thrombolysis patients <i>n</i> = 84			
Hospital stay	7,168 (1,150–35,111)	7,168 (1,150–35,111)	(20)
Rehabilitation stay if mRs ≤ 2	16,073 (4,005–38,181)	16,073 (4,005–38,181)	(20)
Rehabilitation stay if mRs > 2	21,654 (8,277–41,919)	21,654 (8,277–41,919)	(20)
Death at 3 months	10,053 (1,150–25,404)	10,053 (1,150–25,404)	(20)
Telethrombolysis patients <i>n</i> = 16			
Hospital stay	–	10,109 (5,764–17,053)	(20)
Rehabilitation stay if mRs ≤ 2	–	16,073 (4,005–38,181)	(20)
Rehabilitation stay if mRs > 2	–	21,654 (8,277–41,919)	(20)
Death at 3 months	–	11,922 (5,764–16,157)	(20)
Alternative treatment <i>n</i> = 642			
Hospital stay	6,610	6,610	(21)
Rehabilitation stay if mRs ≤ 2	12,282 (801–46,725)	12,282 (801–46,725)	(20)
Rehabilitation stay if mRs > 2	18,156 (534–62,745)	18,156 (534–62,745)	(20)
Death at 3 months	13,018 (6,610–15,421)	13,018 (6,610–15,421)	(20)

EMR, emergency medical regulation; SHT, symptomatic hemorrhagic transformation; mRs, modified Rankin score.

^aThe transition probabilities reported in this table are aggregated transition probabilities.

Table 2. Results of the cost-effectiveness analysis

Severe disability 3 months after stroke	Usual care	Telestroke
Cost (EUR)	10,991	11,088
Incremental cost (EUR)		97
Effectiveness	.2784	.25
Incremental effectiveness		.033
ICER ^a		2,990
Death at 3 months		
Cost (EUR)	11,564	11,718
Incremental cost (EUR)		154
Effectiveness	.1355	.13
Incremental effectiveness		.006
ICER ^b		25,474
Hospital death		
Cost (EUR)	6,677	6,815
Incremental cost (EUR)		138
Effectiveness	.0693	.067
Incremental effectiveness		.002
ICER ^c		74,755

^aICER: incremental cost effectiveness ratio expressed respectively in terms of cost *per* additional avoided severe disability case.

^bCost *per* additional avoided death at 3 months.

^cCost *per* additional avoided hospital death.

treated with thrombolysis or telethrombolysis and with mRs > 2 (baseline value: 81.1 days; min: 31 days; max: 157 days); and 4. “Rehabilitation LOS thrombolysis and telethrombolysis (mRs < 2)” focused on patients treated with thrombolysis or telethrombolysis and with mRs ≤ 2 (baseline value: 60.2 days; min: 15 days; max: 143 days). All the results were presented in a tornado diagram showing the impact of these variations on the baseline ICER, and expressed in terms of the 3-month incremental cost *per* additional avoided case of severe disability.

Results

Baseline Cost-Effectiveness Analysis

As shown in Table 2, the telestroke strategy was slightly more effective and slightly more costly than the usual care strategy, whatever the time horizon. The 3-month analysis for disability criteria revealed that telestroke was the most effective strategy, with 25 disability cases *per* 100 patients compared with 28 for usual care. It was also the costliest, with an extra cost of EUR 97, leading to an ICER of EUR 2,990 *per* additional avoided case of severe disability. The two other analyses showed similar results but with lower incremental effects and cost-savings. An ICER of EUR 25,474 *per* additional avoided death at 3 months was associated with the 3-month death analysis and an ICER of EUR 74,755 *per* additional avoided death at hospital discharge for the hospital death analysis.

Sensitivity Analyses

The results of the one-way sensitivity analyses for the 3-month disability model are presented as a tornado diagram in Figure 2.

Figure 2 shows the robustness of the ICER. The results were consistently in favor of the telestroke network: when the global length of rehabilitation stay parameter ranged from the lowest to highest values, the baseline ICER (EUR 2,990) varied between EUR 670 and EUR 3,707. Other analyses showed that the highest ICER value (EUR 4,652) was obtained for patients treated with an alternative treatment and presenting an mRs > 2. These patients also had the longest rehabilitation stay. In all other cases, telestroke was a dominant strategy (less costly and more effective than usual care) with an ICER ranging from EUR −2,482 to EUR −6,009.

Discussion

The study showed that telestroke was slightly more effective than usual care. In other words, more frequent and quicker access to stroke care reduced – as expected – death and disability after stroke. However, telestroke was slightly more costly than usual care, which can be explained by the higher cost of telethrombolysis care. First, patients had two consecutive hospital stays, one in a local hospital and one in a stroke unit for post-acute monitoring, and second, the cost of a local hospital stay is higher than the cost of a stroke unit stay.

Previous decision analysis studies have demonstrated the efficiency of telestroke over the longer-term (15–18). Among them, two American studies demonstrated that telestroke was cost-effective (under the USD 50,000 *per* QALY threshold) over a lifetime when compared to a scenario with no network (16;18). A similar Danish study revealed that telestroke became the dominant approach after 2 years of implementation (15). However, these results are only partially transferable to French telestroke because, at present, French stroke management standards require a systematic post-acute transfer of telethrombolysis patients, while in the USA transfer from spoke to hub depends on spoke size (medium-size hospitals can keep their stroke patients) (18).

In addition to the long-term results, the two American studies also analyzed the short-term effect of telestroke. Nelson et al. (16) and Demaerschalk et al. (18) found that, while telestroke led to gains in terms of effectiveness, it was also associated with an increase in costs over the yearly time horizon of the study. These results were recently confirmed by another short-term study on the New Mexico telestroke network that described a potential cost-saving of USD 4,241 *per* patient and a gain of .20 QALY over 3 months (20). After consulting with a team of neurologists, we also limited our investigation to a shorter period to be able to attribute the clinical benefit directly to the telestroke network. The main difference between the existing studies and ours was the type of medico-economic evaluation. Cost-effectiveness analyses and cost-utility evaluations are considered complementary (25). However, cost-utility analyses require utility data, which were not available due to the retrospective design of our study. Another difference was the absence of randomization, which is justified by the fact that our cost-effectiveness study was part of the implementation of the telestroke network. In this context, a before/after study was considered relevant, especially since clinical practice guidelines did not change throughout the study period (25).

Decision analysis models have been criticized for the uncertainty generated by the structure and the sources of the implemented parameters. Therefore, the fact that we used local, population-based data when possible is the second main strength of our work. One potential limit of the present study is the relatively small sample size. Theoretically, 1,766




Fig. 2. Tornado diagram: effect of LOS in a rehabilitation unit on the 3-month incremental cost per additional case of avoided severe disability. This figure shows ICERs associated with longer and shorter length of rehabilitation stay for each treatment option. Midline is base-case ICER for 3-month disability (2,990). LOS, length of stay; mRs, modified Rankin Scale. The highest value ICER was EUR 4,652 which corresponded to the highest rehabilitation LOS for alternative treatment with mRS > 2; the lowest value ICER was EUR -6010 which corresponded to the lowest rehabilitation LOS for alternative treatment patient with mRs > 2.

individuals could have been included over the entire study period, but only 42 percent of this eligible population was used to estimate the parameters of the model. This limitation was a result of local organizational constraints. Specifically, we decided to include the seven hospitals with current telestroke activity even though 13 hospitals were technically connected to the network at the start of our study. Since we could not collect comprehensive population-based data, we developed hypotheses to overcome missing data. Seeing as the rehabilitation care standard applied in both situations and because they have similar 3-month outcomes (13), we assumed that telethrombolysis patients and thrombolysis patients had the same average rehabilitation stay. Furthermore, telethrombolysis patients were underrepresented in the sample, which led us to extract three specific parameters from the literature. The rate of symptomatic intracranial hemorrhagic transformations and the cost of stroke for telethrombolysis and thrombolysis patients were obtained from another study conducted in Burgundy (13;23), and the cost of stroke for alternative treatment patients and the daily cost of a rehabilitation stay were based on a national French study (24).

Conclusion

Telestroke is an effective mean of delivering stroke care to remote populations, and there is only a slightly higher cost for the French

health insurance system. The extra cost identified here is partially due to the consecutive stays of telethrombolysis patients in the local hospital and in the stroke unit. Our findings provide critical information that should be weighed in the debate of whether the French telestroke network should be expanded or not. In short, this data could be used to inform policymakers in their efforts to reach national objectives on stroke care.

Acknowledgments. The authors would like to thank the Biostatistics and Bioinformatics service/departement (DIM) of the involved hospitals for helping to identify the included patients and collect the clinical data and the Directions des Affaires Financières (DAF) for providing data on cost of hospital stay. We thank Adrien Roussot, Dr Chantegret, Dr Dreyfus, and Pr Freysz for providing data for the decision model. The authors wish to thank Suzanne Rankin (Dijon University Hospital) for English language editing. This work was supported by the Agence Régionale de Santé de Bourgogne. This research was supported by a French government grant managed by the French National Research Agency under the programme 'Investissements d'Avenir' with reference ANR-11-LABX-0021 (Lipstic Labex).

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0266462320000057>

Author contributions. All authors attest that (1) each author contributed to the conception and design or analysis and interpretation of data and the writing of the paper; (2) each has approved the version being submitted; and (3) the content has not been published nor is being considered for publication elsewhere.

Conflict of Interest. None.

References

1. **GBD 2015 Mortality and Causes of Death Collaborators** (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Lond Engl* **388**, 1459–1544.
2. **Béjot Y, Bailly H, Graber M *et al.*** (2019) Impact of the ageing population on the burden of stroke: the dijon stroke registry. *Neuroepidemiology* **52**, 78–85.
3. **The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group** (1995) Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* **333**, 1581–1588.
4. **Langhorne P, Williams BO, Gilchrist W, Howie K** (1993) Do stroke units save lives? *Lancet Lond Engl* **14**, 395–398.
5. **Hacke W, Kaste M, Bluhmki E *et al.*** (2008) Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. *N Engl J Med* **359**, 1317–1329.
6. **European Stroke Organisation** (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. *Cerebrovasc Dis* **25**, 457–507.
7. **Leys D, Ringelstein EB, Kaste M *et al.*** (2007) Facilities available in European hospitals treating stroke patients. *Stroke* **38**, 2985–2991.
8. **Silva GS, Farrell S, Shandra E, Viswanathan A, Schwamm LH** (2012) The status of telestroke in the United States: A survey of currently active stroke telemedicine programs. *Stroke* **43**, 2078–2085.
9. **Levine SR, Gorman M** (1999) 'Telestroke': the application of telemedicine for stroke. *Stroke* **30**, 464–469.
10. **Johansson T, Wild C** (2010) Telemedicine in acute stroke management: Systematic review. *Int J Technol Assess Health Care* **26**, 149–155.
11. **Delpont B, Blanc C, Mariet AS *et al.*** (2017) Efficacité des filières dédiées à l'Accident Vasculaire Cérébral. Moyens de mesure. Expérience en Bourgogne. *J Gest Econ Médicales* **35**, 18–31.
12. **Walter S, Kostopoulos P, Haass A *et al.*** (2012) Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. *Lancet Neurol* **11**, 397–404.
13. **Legris N, Hervieu-Bègue M, Daubail B *et al.*** (2016) Telemedicine for the acute management of stroke in Burgundy, France: an evaluation of effectiveness and safety. *Eur J Neurol* **23**, 1433–1440.
14. **Caro JJ, Huybrechts KF, Duchesne I** (2000) Management patterns and costs of acute ischemic stroke: An international study. For the Stroke Economic Analysis Group. *Stroke* **31**, 582–590.
15. **Ehlers L, Müskens WM, Jensen LG, Kjølby M, Andersen G** (2008) National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: A model of budgetary impact and cost effectiveness. *CNS Drugs* **22**, 73–81.
16. **Nelson RE, Saltzman GM, Skalarin EJ, Demaerschalk BM, Majersik JJ** (2011) The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. *Neurology* **77**, 1590–1598.
17. **Switzer JA, Demaerschalk BM, Xie J *et al.*** (2013) Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives. *Circ Cardiovasc Qual Outcomes* **6**, 18–26.
18. **Demaerschalk BM, Switzer JA, Xie J *et al.*** (2013) Cost utility of hub-and-spoke telestroke networks from societal perspective. *Am J Manag Care* **19**, 976–985.
19. **Nelson RE, Okon N, Lesko AC *et al.*** (2015) The cost-effectiveness of telestroke in the Pacific Northwest region of the USA. *J Telemed Telecare* **22**, 413–421.
20. **Whetten J, Goes (van der) DN, Tran H *et al.*** (2018) Cost-effectiveness of Access to Critical Cerebral Emergency Support Services (ACCESS): A neuro-emergent telemedicine consultation program. *J Med Econ* **21**, 1–8.
21. **Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW** (2015) *Methods for the economic evaluation of health care programmes*. 4th ed. Oxford: Oxford University Press.
22. **Fagan SC, Morgenstern LB, Petitta A *et al.*** (1998) Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. *Neurology* **50**, 883–890.
23. **Peyron C, Wallut L** (2017) Tarification à l'activité et équilibre financier des prises en charge avec télé-médecine : l'exemple du dispositif TéléAVC en Bourgogne, Financial balance of hospital care in a telestroke network: the case of the TéléAVC network in Burgundy. *J Gest Déconomie Médicales* **34**, 415–429.
24. **Chevreul K, Durand-Zaleski I, Gouépo A *et al.*** (2013) Cost of stroke in France. *Eur J Neurol* **20**, 1094–1100.
25. **Haute Autorité de Santé** (2011) Choix méthodologiques pour l'évaluation économique à la HAS - guide méthodologique [Internet]. Available from: http://www.has-sante.fr/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf. Accessed 2019.